{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:42Z","timestamp":1792787322358,"version":"4.5.0"},"reference-count":23,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"UCL Partners Academic Health Science Centre"},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["205167\/Z\/16\/Z"],"award-info":[{"award-number":["205167\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BRC"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2024,3,27]]},"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Disease-modifying therapies (DMTs) for Alzheimer\u2019s disease (AD) have early evidence of efficacy. Widespread delivery of DMTs will require major service reconfiguration. Treatment pathways will need to include triaging for eligibility, regular infusions and baseline and follow-up MRI scanning. A critical step in planning is provision of real-world estimates of patients likely to be eligible for triaging, but these are challenging to obtain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective service evaluation of patients attending five memory services across North and East London and a national specialist cognitive disorders service. We examined the likely proportion of patients who would (1) be referred for triaging for DMTs and (2) potentially be suitable for treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data from a total of 1017 patients were included, 517 of whom were seen in community memory services and 500 in a specialist clinic. In the memory services, 367\/517 (71%) were diagnosed with possible AD. After exclusions of those in whom cognitive and frailty scores, MRI contraindications or anticoagulant use indicated they would be unlikely to be suitable, an estimated 32% would be eligible for triaging. In the specialist cognitive clinic, where additional investigations are available, 14% of those seen (70\/500) would be potentially eligible for treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While a sizeable proportion of patients attending memory clinics may be referred for triaging for DMTs for AD, only a minority are likely to be suitable for these, as demonstrated in patients seen in specialist cognitive services. This will need to be considered when designing pathways for DMT delivery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2024-333468","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T20:00:22Z","timestamp":1718136022000},"page":"796-803","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":49,"title":["Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer\u2019s disease"],"prefix":"10.1136","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2993-585X","authenticated-orcid":false,"given":"Ruth","family":"Dobson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshad","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uttara","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hina","family":"Asif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ros","family":"Humphreys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eng","family":"O-Charoenrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Huzzey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Clare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maija","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catrin","family":"Sohrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navreen","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirtha","family":"Pasupathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Whiteman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Maxmin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Bass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavya","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8227-2354","authenticated-orcid":false,"given":"Charles","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5092-6325","authenticated-orcid":false,"given":"Rimona Sharon","family":"Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J","family":"Mummery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,6,11]]},"reference":[{"key":"2025021202450616000_95.9.796.1","unstructured":"Dementia Statistics Hub . Dementia Statistics Hub, 2016. Available: https:\/\/dementiastatistics.org\/"},{"key":"2025021202450616000_95.9.796.2","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.b.32684"},{"key":"2025021202450616000_95.9.796.3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of Aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"2025021202450616000_95.9.796.4","unstructured":"US Food and Drug Administration . Aducanumab (marketed as Aduhelm) information. 2022. Available: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/aducanumab-marketed-aduhelm-information"},{"key":"2025021202450616000_95.9.796.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJ-Moa2212948"},{"key":"2025021202450616000_95.9.796.6","unstructured":"U.S. Food and Drug Administration . FDA converts novel Alzheimer\u2019s disease treatment to traditional approval. 2023. Available: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-converts-novel-alzheimers-disease-treatment-traditional-approval"},{"key":"2025021202450616000_95.9.796.7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2100708"},{"key":"2025021202450616000_95.9.796.8","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"2025021202450616000_95.9.796.9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.14283\/jpad.2022.56","article-title":"Amyloid-related imaging abnormalities and other MRI findings in a cognitively unimpaired population with and without cerebral Amyloid","volume":"9","author":"Yaari","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"2025021202450616000_95.9.796.10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3233\/JAD-210089","article-title":"The influence of socioeconomic deprivation on dementia mortality, age at death, and quality of diagnosis: A nationwide death records study in England and Wales 2001-2017","volume":"81","author":"Jitlal","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"2025021202450616000_95.9.796.11","unstructured":"Breton C . Clinical frailty scale, Available: https:\/\/www.bgs.org.uk\/sites\/default\/files\/content\/attachment\/2018-07-05\/rockwood_cfs.pdf"},{"key":"2025021202450616000_95.9.796.12","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"2025021202450616000_95.9.796.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2009.01918.x"},{"key":"2025021202450616000_95.9.796.14","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1017\/S104161021700268X","article-title":"Conversion between Addenbrooke\u2019s cognitive examination III and mini-mental state examination","volume":"30","author":"Mat\u00edas-Guiu","year":"2018","journal-title":"Int Psychogeriatr"},{"key":"2025021202450616000_95.9.796.15","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/alz.12444","article-title":"Aducanumab: appropriate use recommendations","volume":"18","author":"Cummings","year":"2022","journal-title":"Alzheimers Dement"},{"key":"2025021202450616000_95.9.796.16","unstructured":"Royal college of psychiatrists. n.d. Available: https:\/\/www.rcpsych.ac.uk\/docs\/default-source\/improving-care\/ccqi\/quality-networks\/memory-clinics-msnap\/msnap-national-report-(2023)2400cc4f-9e00-46ee-a132-5e834740f770.pdf?Status=Master&sfvrsn=4b7bdbed_10"},{"key":"2025021202450616000_95.9.796.17","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.17530"},{"key":"2025021202450616000_95.9.796.18","doi-asserted-by":"crossref","first-page":"e1837","DOI":"10.1212\/WNL.0000000000207770","article-title":"Eligibility for anti-Amyloid treatment in a population-based study of cognitive aging","volume":"101","author":"Pittock","year":"2023","journal-title":"Neurology"},{"key":"2025021202450616000_95.9.796.19","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0b013e31824b211b"},{"key":"2025021202450616000_95.9.796.20","doi-asserted-by":"crossref","unstructured":"Togher Z , Dolphin H , Russell C , et al . Potential eligibility for Aducanumab therapy in an Irish specialist cognitive service-Utilising cerebrospinal fluid biomarkers and appropriate use criteria. Int J Geriatr Psychiatry 2022;37. doi:10.1002\/gps.5789","DOI":"10.1002\/gps.5789"},{"key":"2025021202450616000_95.9.796.21","doi-asserted-by":"crossref","first-page":"e2102","DOI":"10.1212\/WNL.0000000000201043","article-title":"\u0392-Amyloid, Tau, neurodegeneration classification and eligibility for anti-Amyloid treatment in a memory clinic population","volume":"99","author":"Rosenberg","year":"2022","journal-title":"Neurology"},{"key":"2025021202450616000_95.9.796.22","doi-asserted-by":"crossref","unstructured":"Laurell AAS , Venkataraman AV , Schmidt T , et al . Estimating demand for potential disease-modifying therapies for Alzheimer\u2019s disease in the UK. Br J Psychiatry 2024;1\u20137. doi:10.1192\/bjp.2023.166","DOI":"10.1101\/2023.11.17.23298682"},{"key":"2025021202450616000_95.9.796.23","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1001\/jamaneurol.2023.4046","article-title":"APOE genotype in the era of disease-modifying treatment with Monoclonal antibodies against Amyloid-\u0392","volume":"80","author":"Ossenkoppele","year":"2023","journal-title":"JAMA Neurol"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2024-333468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T05:45:43Z","timestamp":1739339143000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2024-333468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,11]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,8,16]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1136\/jnnp-2024-333468"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2024-333468","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,11]]}}}